Apolipoprotein A-V (APOA5) Antibody
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately four fold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 50–70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor- agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Despite these compelling molecular biology data, relatively little is known about ApoA5 protein in human serum. This antibody pair detected recombinant apoa5 protein in sandwich ELISA format and could be potential reagents for the development of clinical diagnostic kits.
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Apolipoprotein A-V (APOA5) |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | ELISA: 1/10000, IF/ICC: 1/200 - 1/1000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG1 |
| Purification | Unpurified ascites. |
| Size 1 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA, IF/ICC |
| Buffer | Ascitic fluid containing 0.03% sodium azide. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q6Q788 |
| Gene ID | 116519 |
| OMIM | 144650 |
| Alias | APOA5, APOAV, RAP3, apolipoprotein A5, APO A5,APO A-5,Apolipoprotein A-V |
| Background | Antibody anti-APOA5 |
| Status | RUO |
| Note | Concentration: Not determined. - |
Descripción
APOA5 is a critical regulator of plasma triglyceride (TG) levels, playing an essential role in lipid metabolism and cardiovascular health It is primarily synthesized in the liver and is a minor apolipoprotein component of chylomicrons and very-low-density lipoproteins (VLDL) APOA5 functions by enhancing the activity of lipoprotein lipase (LPL), which hydrolyzes triglycerides in VLDL and chylomicrons, thereby reducing plasma triglyceride levels Genetic variants in the APOA5 gene are strongly associated with hypertriglyceridemia, which is a major risk factor for cardiovascular diseases (CVD), atherosclerosis, and pancreatitis APOA5 interacts with cell surface receptors such as GPIHBP1 to facilitate LPL activity and triglyceride clearance from the bloodstream Studies have shown that reduced APOA5 expression leads to elevated triglycerides and increased risk of metabolic syndrome APOA5 also modulates lipid storage in adipose tissue, highlighting its broader role in lipid homeostasis APOA5 is being investigated as a therapeutic target for hyperlipidemia and related cardiovascular conditions, as strategies enhancing APOA5 expression or function may improve triglyceride metabolism and reduce cardiovascular risks
Related Products
Human APOA5(Apolipoprotein A-V) ELISA Kit
Ver Producto
Apolipoprotein A-V (APOA5) Antibody
APOA5 Antibody is a Rabbit Polyclonal antibody against APOA5. Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately four fold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 50–70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor- agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Despite these compelling molecular biology data, relatively little is known about ApoA5 protein in human serum.This antibody pair detected recombinant apoa5 protein in sandwich ELISA format and could be potential reagents for the development of clinical diagnostic kits.
Ver Producto
Apolipoprotein A-V (APOA5) Antibody
Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately four fold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 50–70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor- agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Despite these compelling molecular biology data, relatively little is known about ApoA5 protein in human serum. This antibody pair detected recombinant apoa5 protein in sandwich ELISA format and could be potential reagents for the development of clinical diagnostic kits.
Ver Producto